Objectives
==========

To assess the efficacy and safety of a single dose of parecoxib sodium 40 mg IV given 30--45 min preoperatively, followed by oral valdecoxib 40 mg every day for pain given for up to 7 days postsurgery.

Methods
=======

This was a multicenter, randomized, double-blind, parallel-group trial. All patients received standard of care (SOC) fentanyl on demand for pain during the immediate postoperative period and acetaminophen 500 mg/hydrocodone 5 mg PO every 4--6 hours as required (for pain) following discharge for up to day 7 postsurgery. The active arm received, in addition, parecoxib sodium 40 mg IV administered 30--45 min preoperatively and valdecoxib 40 mg every day initiated 6--12 hours after surgery and continued up to day 7 postsurgery. The comparator arm received placebo (SOC) matched for the parecoxib sodium and valdecoxib. Pain was evaluated daily using the modified Brief Pain Inventory (mBPI) with \'Worst Pain\' assessed using a 0--10 numerical rating scale (NRS) where 10 = worst pain imaginable.

Results
=======

In the cohort (*n* = 223) during the immediate postoperative period (4 hours), the parecoxib sodium group (*n* = 119) required significantly lower amounts of fentanyl (152.8 μg vs 192.9 μg: *P* = 0.011) than the comparator group (*n* = 104). Significantly fewer patients in the valdecoxib group required supplemental analgesia over days 1--5 postsurgery (*P* \< 0.02). \'Worst Pain\' scores were also statistically significantly improved in the valdecoxib-treated group compared with placebo (SOC). Percent of patients reporting worst pain as none or mild (NRS ≤ 4) in the valdecoxib and placebo (SOC) group on day 1 was 63.1% vs 29.2% (*P* \< 0.001); day 2 69.2% vs 56.0%. The most common adverse events were nausea, headache, constipation, pain, fatigue and diarrhea, which were comparable between groups.

Conclusions
===========

Preoperative administration of parecoxib sodium 40 mg IV resulted in significant opioid sparing immediately following laparoscopic cholecystectomy surgery. Valdecoxib 40 mg every day provided significant opioid-sparing effects and reduced \'Worst Pain\' levels in these patients following discharge. Both parecoxib sodium and valdecoxib were well tolerated.
